Evidence map›Paper›PMID 38319527›Full record

ReviewStem cell reviews and reports2024

New Perspectives in Stem Cell Transplantation and Associated Therapies to Treat Retinal Diseases: From Gene Editing to 3D Bioprinting.

Gabrieli Bovi Dos Santos, Théo Henrique de Lima-Vasconcellos, Marília Inês Móvio, Alexander Birbrair, Carolina Beltrame Del Debbio, Alexandre Hiroaki Kihara

Abstract readReview
PubMed Publisher
In one paragraph

Review in Stem cell reviews and reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Gabrieli Bovi Dos SantosLaboratório de Neurogenética, Universidade Federal do ABC, São Bernardo do Campo, Santo André, SP, Brazil.
Théo Henrique de Lima-VasconcellosLaboratório de Neurogenética, Universidade Federal do ABC, São Bernardo do Campo, Santo André, SP, Brazil.
Marília Inês MóvioLaboratório de Neurogenética, Universidade Federal do ABC, São Bernardo do Campo, Santo André, SP, Brazil.
Alexander BirbrairDepartment of Dermatology, Medical Sciences Center, University of Wisconsin-Madison, Rm 4385, 1300 University Avenue, Madison, WI, 53706, USA.
Carolina Beltrame Del DebbioDepartamento de Biologia Celular e do Desenvolvimento, Instituto de Ciências Biomédicas, Universidade de São Paulo USP, São Paulo, SP, Brazil.
Alexandre Hiroaki KiharaLaboratório de Neurogenética, Universidade Federal do ABC, São Bernardo do Campo, Santo André, SP, Brazil. alexandrekihara@gmail.com.ORCID 0000-0002-4027-7261
Universidade Federal do ABC · BRUniversidade de São Paulo · BRUniversity of Wisconsin–Madison · US

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 312047/2017-7Conselho Nacional de Desenvolvimento Científico e Tecnológico 315372/2021-4Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 001Fundação de Amparo à Pesquisa do Estado de São Paulo 2017/26388-6Fundação de Amparo à Pesquisa do Estado de São Paulo 2019/17892-8Fundação de Amparo à Pesquisa do Estado de São Paulo 2020/02035-0Fundação de Amparo à Pesquisa do Estado de São Paulo 2020/11667-0Fundação de Amparo à Pesquisa do Estado de São Paulo 2021/03711-1Fundação de Amparo à Pesquisa do Estado de São Paulo 2021/11969-9Fundação de Amparo à Pesquisa do Estado de São Paulo 2021/14227-3
6 · The paper itself

Abstract

Inherited and non-inherited retinopathies can affect distinct cell types, leading to progressive cell death and visual loss. In the last years, new approaches have indicated exciting opportunities to treat retinopathies. Cell therapy in retinitis pigmentosa, age-related macular disease, and glaucoma have yielded encouraging results in rodents and humans. The first two diseases mainly impact the photoreceptors and the retinal pigmented epithelium, while glaucoma primarily affects the ganglion cell layer. Induced pluripotent stem cells and multipotent stem cells can be differentiated in vitro to obtain specific cell types for use in transplant as well as to assess the impact of candidate molecules aimed at treating retinal degeneration. Moreover, stem cell therapy is presented in combination with newly developed methods, such as gene editing, Müller cells dedifferentiation, sheet & drug delivery, virus-like particles, optogenetics, and 3D bioprinting. This review describes the recent advances in this field, by presenting an updated panel based on cell transplants and related therapies to treat retinopathies.

Indexed as

BioprintingGlaucomaHematopoietic Stem Cell TransplantationRetinal DegenerationGene EditingHumansStem Cell Transplantation3D bioprintingCell therapyGene editingInduced pluripotent stem cellOptogeneticsRetina

Identifiers

PMID38319527
OpenAlexW4391574801

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.